Aerie Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2015 along with a general business update. Aerie Highlights Efficacy results from Aerie’s RhopressaTM Rocket 2 trial, using the primary clinical endp
